Back

A biopsy-based pilot clinical study: monitoring the effectiveness of tafamidis treatment of patients with transthyretin amyloid cardiomyopathy.

25 August 2023 (15:15 - 15:50)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis: prognosis and treatment monitoring Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Ahmed Elsanhoury

Charite University Hospital, Berlin (Germany)

6 More presentations in this session

Presentation thumbnail
Prognostic value of different echocardiographic and cardiac magnetic resonance parameters in patients with AL amyloidosis
Doctor A. Hernandez Martos (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Echo-derived hemodynamic categorization for risk stratification in transthyretin cardiac amyloidosis
Doctor A. Cantone (Ferrara, IT)
Abstract Slides Video
Presentation thumbnail
The electrophysiological substrate of biopsy-proven cardiac amyloidosis
Associate Professor M. Casella (Ancona, IT)
Abstract Slides Video
Presentation thumbnail
Interleukin-6 plasma levels predict mortality and heart failure events in cardiac transthyretin amyloidosis
Mr J. Lugitsch (Salzburg, AT)
Abstract Slides Video
Presentation thumbnail
Temporal trends and outcomes of heart failure patients between light-chain cardiac amyloidosis and transthyretin cardiac amyloidosis: insights from the national inpatient sample database
Doctor K. Gandhi (New York, US)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac amyloidosis: prognosis and treatment monitoring

The Event

Event poster

ESC Congress 2023

25 August 2023 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Serial changes of 99mTc- pyrophosphate uptake in patients with hereditary transthyretin amyloid cardiomyopathy treated with tafamidis
thumbnail
Congress Presentation
Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.
thumbnail
Congress Presentation
Improvements in cardiac functional status and health-related quality of life in patients receiving early access tafamidis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources